Eight months into his tenure, Johnson & Johnson’s R&D chief is placing a giant emphasis on medicines for most cancers, treatment-resistant despair, and autoimmune illness.
To sharpen that focus, R&D chief John Reed informed STAT that the corporate is de-emphasizing two areas which were mainstays for the drug and medical system large: infectious illness and vaccines, in addition to medicines focusing on kidney illness and uncommon eye situations.
The disclosures had been made in an interview forward of an investor assembly Reed is main Tuesday geared toward producing pleasure in regards to the firm’s analysis and improvement efforts.